U.S. Single-Use Gastroenterology Devices Market: $8.12B

Market Outlook

By 2032, the U.S. Single-Use Gastroenterology Devices Market is projected to reach approximately USD 8.12 billion, expanding at a CAGR of 16.89% during the forecast period 2027–2032. The market stood at USD 3.18 billion in 2026, following historical values of approximately USD 1.92 billion in 2023, USD 2.26 billion in 2024, and USD 2.68 billion in 2025. Values in this report are expressed in USD billions.

The U.S. single-use gastroenterology devices industry sits at the convergence of infection control imperatives, hospital capital reallocation, advanced complementary metal-oxide-semiconductor imaging miniaturization, ambulatory procedural migration, and expanding screening recommendations for gastrointestinal diseases. Demand is fundamentally underpinned by clinical necessity and regulatory scrutiny surrounding the persistent, documented risks of patient cross-contamination associated with complex, reusable flexible endoscopes, most notably duodenoscopes, gastroscopes, and echoendoscopes. In the United States, gastrointestinal endoscopy represents one of the highest-volume procedural categories in modern medicine, with more than 22 million endoscopic procedures conducted annually across inpatient hospital surgical departments, hospital outpatient departments, and independent ambulatory surgery centers.

The clinical architecture of traditional reusable flexible endoscopes, engineered with long, narrow, inaccessible internal lumens, intricate distal elevator mechanisms, and delicate bending sections, makes absolute high-level disinfection and sterilization exceedingly difficult to achieve in routine clinical practice. Multidrug-resistant organism outbreaks, particularly carbapenem-resistant Enterobacteriaceae and extended-spectrum beta-lactamase-producing bacteria, have been systematically traced to persistent bio-burden trapped within the elevator channels of reprocessed duodenoscopes, even when facilities adhered strictly to manufacturer-validated reprocessing protocols. These clinical realities have catalyzed an unprecedented regulatory intervention by the U.S. Food and Drug Administration, prompting safety communications, post-market surveillance mandates, and recommendations for healthcare facilities to transition toward devices with disposable components or entirely single-use, sterile endoscopic platforms.

The consolidation and institutional modernization of healthcare delivery networks have dramatically shifted procurement frameworks from capital-intensive equipment acquisitions toward predictable, procedure-linked operating expenditure models. Healthcare systems are navigating compressed operating margins, volatile capital financing costs, and acute labor shortages within central sterile processing departments. By adopting fully single-use gastroenterology devices, health systems eliminate the extensive recurring capital and operational overhead associated with automated endoscope reprocessors, hazardous peracetic acid or glutaraldehyde chemical solutions, borescope channel inspection systems, microbiologic surveillance culturing, channel repair contracts, and dedicated decontamination staffing.

Concurrently, the historical perception that disposable endoscopy systems compromise optical resolution, tactile torque response, or therapeutic accessory compatibility has been dismantled by rapid engineering advancements. Contemporary single-use endoscopes and their associated disposable therapeutic accessories incorporate high-definition wafer-level chip-on-tip video sensors, micro-light-emitting diode illumination arrays, variable-stiffness polymer insertion tubes, and precision articulation wires that match the diagnostic visualization and mechanical maneuverability of legacy premium reusable platforms. Manufacturers are pairing these high-performance optical platforms with ergonomic handles engineered to reduce endoscopist musculoskeletal fatigue and repetitive strain injuries during high-throughput procedural schedules.

The historical market expanded aggressively from 2023 through 2025 as hospital procurement committees, gastroenterology group practices, and ambulatory surgery centers accelerated trial deployments of single-use duodenoscopes and advanced single-use therapeutic accessories, driven by post-pandemic backlogs of gastrointestinal procedures and heightened institutional liability awareness regarding hospital-acquired infections. From 2027 onward, market growth will be sustained by the widespread clinical normalization of single-use gastroscopes and colonoscopes, favorable Medicare and commercial payer reimbursement structures, targeted single-use therapeutic access catheters, and the complete institutional phase-out of legacy fixed-elevator reusable duodenoscopes across U.S. endoscopy suites.

Introduction

According to the U.S. Single-Use Gastroenterology Devices Market Report, gastroenterology intervention represents one of the most critical and economically vital sectors of the American healthcare delivery landscape, defined by a structural transition from empirical, reprocessing-dependent procedural models toward fully sterile, unit-dosed single-use technology. A gastrointestinal patient traverses a sophisticated, high-acuity diagnostic and therapeutic continuum. A patient may present for routine colorectal cancer screening requiring a colonoscope and disposable polypectomy snares, undergo urgent intervention for upper gastrointestinal hemorrhaging requiring a gastroscope paired with single-use hemostatic clips and injection needles, require advanced biliary decompression for obstructive jaundice via endoscopic retrograde cholangiopancreatography utilizing a single-use duodenoscope and disposable sphincterotomes, or receive staging for a pancreatic malignancy via endoscopic ultrasound with single-use fine-needle aspiration systems.

This clinical care continuum establishes a commercially robust ecosystem characterized by the rapid displacement of depreciable capital towers in favor of high-velocity, recurring consumable revenue streams. Single-use endoscopes, encompassing duodenoscopes, gastroscopes, colonoscopes, and cholangioscopes, constitute the vanguard of this commercial transformation, supported by an extensive installed volume of sterile disposable therapeutic accessories, including biopsy forceps, extraction balloons, guidewires, hemoclips, and dilation devices. The operational economics of modern endoscopy centers dictate that procedural suites must maximize room turnover efficiency, eliminate cross-contamination liabilities, and maintain predictable per-case margin profiles. Unlike traditional hospital capital cycles, which lock health systems into seven-to-ten-year depreciation schedules with punitive ongoing maintenance contracts, single-use endoscopy establishes a transparent per-procedure variable cost structure that aligns directly with third-party billing schedules.

The operational reality of central sterile processing departments has exposed systemic vulnerabilities in the reusable endoscopy paradigm. The reprocessing of a single reusable flexible endoscope involves over one hundred discrete, manual, technician-dependent steps, encompassing immediate bedside pre-cleaning, leak testing, manual chemical brushing, automated cycle processing, alcohol flushes, and forced-air lumen drying, followed by specialized vertical hanging cabinet storage. Human procedural deviations, high staff turnover, inadequate training, and micro-wear within internal lumens create persistent failure points where biofilm, desiccated blood, and pathogenic microorganisms harbor and proliferate. Published multi-center clinical trials in the United States have demonstrated persistent microbial contamination rates between 5% and 15% on fully reprocessed, patient-ready reusable duodenoscopes and gastroscopes. The financial fallout of a single hospital-acquired multidrug-resistant organism outbreak, encompassing epidemiological contact tracing, intensive care hospitalization, regulatory fines, and legal liability settlements, routinely exceeds several million dollars, far eclipsing the incremental acquisition cost of single-use sterile devices.

The evolution of third-party reimbursement has played a transformative role in accelerating market adoption. The Centers for Medicare & Medicaid Services has recognized the clinical and public health value of single-use endoscopy, establishing dedicated Healthcare Common Procedure Coding System Level II codes and Transitional Pass-Through payment mechanisms for innovative single-use duodenoscopes utilized in hospital outpatient departments and ambulatory surgery centers. By providing supplemental reimbursement over and above standard Comprehensive Ambulatory Payment Classifications, Medicare has mitigated the initial cost differential between reusable reprocessing and single-use acquisition, incentivizing clinical administrators to transition high-risk procedures immediately toward single-use instrumentation.

The rapid migration of gastrointestinal procedures from hospital inpatient surgical suites to independent ambulatory surgery centers has further altered device purchasing criteria. Ambulatory surgery centers operate with lean operational footprints, minimal storage square footage, and optimized nurse-to-patient ratios. Constructing, maintaining, and certifying a dedicated negative-pressure chemical decontamination suite with specialized plumbing, toxic vapor ventilation, and water purification systems imposes prohibitive physical and financial barriers on outpatient operators. Single-use gastroenterology devices eliminate the need for centralized decontamination rooms entirely, enabling ambulatory surgery centers to repurpose expensive square footage into revenue-generating procedural bays or patient recovery areas while accelerating room turnover times from forty-five minutes down to fifteen minutes between cases.

From 2027 through 2032, device vendors will compete across comprehensive, fully integrated gastroenterology hardware and consumable ecosystems. Market differentiation will no longer depend solely on individual scope optics, but on the ability of manufacturers to deliver unified single-use suites that combine high-definition chip-on-tip visualization, intuitive plug-and-play processing consoles, comprehensive portfolios of high-precision therapeutic accessories, integrated computer-aided diagnostic algorithms, and closed-loop medical plastics recycling logistics that address institutional environmental sustainability mandates.

Key Market Drivers: What’s Fueling the U.S. Single-Use Gastroenterology Devices Market Boom?

The first primary growth driver is the regulatory pressure and infection control imperatives enforced by the U.S. Food and Drug Administration, the Centers for Disease Control and Prevention, and professional healthcare accreditation bodies. Following high-profile, fatal outbreaks of carbapenem-resistant Enterobacteriaceae linked to contaminated duodenoscopes across prominent American medical centers, the FDA issued a series of escalating safety communications and mandated 522 post-market surveillance studies. The regulatory findings conclusively established that reusable fixed-endcap duodenoscopes possess design features that preclude consistent, reliable high-level disinfection in real-world clinical environments. The FDA formally recommended that healthcare providers transition away from conventional fixed-cap duodenoscopes toward devices with disposable components or fully single-use, sterile duodenoscope platforms. This regulatory stance has established an unyielding clinical mandate across hospital risk management committees, accelerating the wholesale replacement of legacy reusable inventories with single-use alternatives to protect institutional accreditation and mitigate medical malpractice vulnerabilities.

A second driver is the clinical and economic burden of hospital-acquired infections caused by multidrug-resistant pathogens. Healthcare-associated infections represent one of the leading causes of preventable patient mortality in the United States, imposing an estimated annual financial burden exceeding USD 30 billion on the American healthcare system. Under the Affordable Care Act and Medicare’s Hospital-Acquired Condition Reduction Program, hospitals in the worst-performing quartile face mandatory, non-negotiable financial penalties, including a 1% reduction in total Medicare inpatient reimbursement across all hospital discharges. Furthermore, commercial health insurers increasingly refuse to reimburse treatment costs associated with secondary nosocomial infections acquired during an elective or emergency inpatient stay. Given that treating a single systemic bloodstream infection or sepsis event resulting from a contaminated endoscope can cost between USD 50,000 and USD 150,000, healthcare chief financial officers and infection control directors are actively deploying single-use gastrointestinal devices as an absolute preventative firewall against catastrophic institutional cost exposure.

A third driver is the favorable restructuring of reimbursement pathways and targeted pass-through payment policies enacted by the Centers for Medicare & Medicaid Services. Historically, the absence of distinct, dedicated device reimbursement disincentivized hospitals from absorbing the per-unit cost of disposable scopes within bundled procedural payments. Recognizing that infection prevention requires capital incentivization, CMS introduced dedicated C-codes under the Outpatient Prospective Payment System and Ambulatory Surgical Center payment frameworks, providing transitional pass-through reimbursement for qualified single-use duodenoscopes. These supplemental payments directly cover the device acquisition cost, allowing endoscopy units to realize the clinical and operational benefits of sterile, single-use systems without compromising departmental procedural contribution margins. This reimbursement structure has democratized access to single-use platforms, enabling community hospitals and outpatient facilities to compete directly with premier academic medical centers in offering zero-infection-risk endoscopic procedures.

A fourth driver is the massive migration of procedural volumes from hospital inpatient settings toward ambulatory surgery centers and specialized outpatient endoscopy clinics. Supported by payer site-of-care steerage policies and patient preferences for accessible, low-friction clinical environments, more than 60% of all screening and diagnostic gastrointestinal procedures in the United States are now performed in outpatient settings. For an ambulatory surgery center, the capital expenditure required to purchase multiple reusable scope towers, install automated endoscope reprocessors, build out chemical exhaust infrastructure, and maintain redundant scope inventories to manage drying cycle backlogs is economically prohibitive. Single-use endoscopy shifts this heavy capital expenditure into a variable operating expense that scales linearly with patient volume. Furthermore, the rapid room turnaround enabled by single-use devices, where a used scope is simply disconnected and packaged for recycling rather than subjected to multi-hour chemical cycling, allows outpatient facilities to increase daily procedural capacity by two to three cases per procedural suite, driving immense operational profitability.

A fifth driver is the chronic, structural labor crisis and high turnover rates within hospital central sterile processing departments. Central sterile processing technicians represent one of the most volatile and understaffed segments of the modern healthcare workforce. Manual cleaning of flexible endoscopes requires meticulous adherence to complex, non-intuitive multi-step protocols involving microscopic brush passes, specific chemical contact durations, and rigorous lumen flushing. Technician fatigue, inadequate training, high turnover, and reliance on expensive temporary travel staffing severely degrade reprocessing protocol compliance. Healthcare systems increasingly view single-use devices as a vital operational de-risking strategy that insulates procedural schedules from technical labor shortages, eliminates human error in scope decontamination, and allows lean nursing staff to focus entirely on direct patient clinical care.

A sixth driver is the rapid advancement in micro-optics, complementary metal-oxide-semiconductor sensor architecture, and low-cost digital signal processing. Historically, single-use endoscopic prototypes suffered from inferior image fidelity, poor dynamic range, restricted depth of field, and sluggish mechanical articulation compared to premium reusable glass-fiber and charge-coupled device systems. The democratization of high-resolution micro-CMOS sensors, paired with micro-aperture lenses and high-efficiency LED illumination arrays, has closed the performance gap completely. Modern single-use endoscopes deliver crisp, high-definition 1080p and 4K digital video outputs, wide-angle 140-degree to 170-degree fields of view, digital chromoendoscopy modes for enhanced mucosal tissue contrast, and responsive four-way mechanical tip deflection. Gastroenterologists are no longer asked to compromise their clinical diagnostic acuity or therapeutic precision to achieve infection prevention.

Finally, the expanding demographic burden of digestive diseases and the lowering of national colorectal cancer screening age thresholds are driving unprecedented procedural demand. In 2021, the U.S. Preventive Services Task Force officially lowered the recommended starting age for average-risk colorectal cancer screening from 50 to 45 years, instantly expanding the eligible screening population by roughly 21 million Americans. Concurrently, the rising national prevalence of non-alcoholic fatty liver disease, obesity-related gastroesophageal reflux disease, Barrett’s esophagus, biliary lithiasis, and early-onset gastrointestinal malignancies has driven procedural waiting lists to historic highs across the United States. Meeting this clinical throughput requirement is physically impossible utilizing legacy reusable scope fleets constrained by long reprocessing turnaround cycles, solidifying the role of high-throughput single-use devices as an indispensable operational necessity.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation across the U.S. single-use gastroenterology devices market is redefining the mechanical, optical, and operational boundaries of flexible endoscopy. Manufacturers are moving aggressively beyond rudimentary disposable designs to engineer sophisticated, intelligent, and environmentally conscious platforms that challenge the long-standing supremacy of high-end reusable endoscopy suites.

The core optical engine of single-use endoscopy has undergone a revolutionary leap through the deployment of advanced wafer-level optics and ultra-miniaturized CMOS image sensors. Historically, placing high-resolution video sensors and illumination fibers into a catheter-scale distal tip resulted in bulky, rigid distal ends that impaired patient comfort and compromised articulation radius. Today, leading manufacturers utilize sub-millimeter CMOS sensor packages measuring less than 1.0 square millimeter, mounted directly at the distal tip alongside multi-element injection-molded optical lenses and high-luminosity micro-LED arrays. These chip-on-tip architectures eliminate the heavy, fragile glass fiber-optic bundles characteristic of legacy scopes, delivering uncompressed digital video signals with exceptional signal-to-noise ratios, deep depth of field, and instantaneous dynamic light correction directly to modular display consoles.

Mechanical articulation and torque transmission represent another vital innovation frontier. The clinical efficacy of a colonoscope, gastroscope, or duodenoscope depends entirely on the physician’s ability to transmit rotational torque from the control handle through the flexible shaft to the distal tip, navigating tortuous colonic flexures, retroflexing within the gastric fundus, or cannulating the ampulla of Vater. Leading single-use developers have engineered proprietary multi-durometer polymer extrusion shafts featuring variable-stiffness braiding and specialized low-friction coatings. These advanced shafts provide high column strength for pushing power while maintaining progressive radial flexibility to mitigate patient discomfort and reduce perforation risks. Distal bending sections now incorporate laser-cut stainless-steel articulating skeletons driven by precision micro-cable pull wires, achieving 210-degree up/down deflection and 180-degree lateral deflection with zero mechanical hysteresis or play.

In the highly specialized therapeutic arena of endoscopic retrograde cholangiopancreatography, innovation has focused intensively on single-use duodenoscope elevator design and cannulation control. Traditional reusable duodenoscopes feature a fixed, exposed mechanical elevator wire and recess that trap biological matter and defy brushing access. Single-use duodenoscopes integrate a completely sterile, precision-molded mechanical elevator directly into the disposable scope head. This mechanism provides precise, micro-metric control over the deflection of sphincterotomes, guidewires, and extraction catheters, allowing sub-millimeter therapeutic alignment with the bile and pancreatic ducts. By ensuring that the elevator mechanism, articulation cables, and working channel are entirely sterile and unused for every single case, single-use platforms deliver pristine mechanical responsiveness, eliminating the loose, worn, or uncalibrated elevator performance frequently encountered in aging, repeatedly autoclaved reusable scopes.

Therapeutic accessory integration has evolved toward pre-packaged, procedure-specific single-use delivery suites. Rather than sourcing disparate components across multiple vendors, gastroenterologists are increasingly utilizing cohesive procedure kits designed to interface seamlessly with specific single-use scopes. For complex gastrointestinal hemostasis, manufacturers have commercialized sterile single-use kits combining ultra-slim endoscopes with pre-loaded, multi-fire through-the-scope hemostatic clips, motorized injection needles with dynamic pressure regulation, and disposable bipolar coagulation probes. In the lower gastrointestinal tract, single-use cold and hot polypectomy snares are engineered with specialized diamond and hexagonal loop geometries utilizing high-tensile braided nitinol wire, providing superior tissue grip, clean mucosal cutting margins, and immediate polyp retrieval capabilities without risk of mechanical deformation or electrical shorting.

The intersection of edge artificial intelligence and single-use hardware is transforming diagnostic visualization into an intelligent, computer-aided clinical workflow. Modern single-use gastroenterology consoles are equipped with embedded neural-network processing units running computer-aided detection and computer-aided characterization algorithms. During screening colonoscopies or upper endoscopies, these edge-AI systems analyze real-time video feeds at sixty frames per second, automatically identifying, highlighting, and classifying subtle, flat, or diminutive mucosal polyps and dysplastic lesions with bounding visual boxes. Furthermore, digital chromoendoscopy modes simulate narrow-band imaging or blue-light mucosal enhancement through advanced spectral post-processing algorithms embedded directly within the single-use console, eliminating the need for expensive, proprietary optical filters while significantly elevating adenoma detection rates among community endoscopists.

Addressing institutional environmental, social, and governance mandates has become an existential focus for single-use medical device manufacturers. The widespread adoption of single-use endoscopy inherently generates significant volumes of clinical plastic waste, prompting valid institutional concerns regarding medical landfill contributions and hospital carbon footprints. In response, leading medtech innovators have established comprehensive, closed-loop sustainability programs. Modern single-use endoscopes are increasingly fabricated utilizing bio-based and recyclable high-performance polymers that can be disassembled efficiently following clinical use. Manufacturers partner with certified medical waste recycling organizations to provide hospitals with dedicated recovery receptacles. The collected single-use scopes undergo non-combustion thermal decontamination and automated shredding, transforming clinical polymers into raw plastic feedstocks for non-clinical industrial manufacturing or energy recovery, thereby offsetting the operational carbon footprint and aligning single-use clinical safety with institutional environmental responsibilities.

Ergonomic engineering represents the final, vital frontier of single-use device design. Repetitive strain injuries, carpal tunnel syndrome, cervical radiculopathy, and thumb tendinitis represent severe occupational hazards affecting over 70% of practicing gastroenterologists due to the weight and awkward gripping torque of heavy reusable scope heads. Single-use endoscopes, unencumbered by heavy metal internal valves, glass optical conduits, and dense sealing housings, achieve a 40% to 50% weight reduction compared to reusable alternatives. Control handles are sculpted with contoured, bio-mechanical grips, reduced-throw articulation wheels, and low-activation-force suction and air/water valves, substantially mitigating physical strain during long procedural blocks and preserving physician career longevity.

Segmentation Insights

The U.S. Single-Use Gastroenterology Devices Market is segmented on the basis of product category, procedure type, indication, technology and modality, end user, and geography.

By Product Category

The U.S. Single-Use Gastroenterology Devices Market by product category is segmented into Single-Use Endoscopes, Endoscopic Resection and Polypectomy Devices, Biliary and Pancreatic Access Devices, Hemostasis and Ligation Devices, Gastrointestinal Biopsy and Sampling Devices, and Endoscopic Dilation and Retrieval Devices.

Single-Use Endoscopes
Single-use endoscopes represent the premier and fastest-expanding capital-displacing product category, accounting for USD 1.38 billion in 2026, up from USD 0.78 billion in 2023, USD 0.94 billion in 2024, and USD 1.14 billion in 2025. The category is projected to reach USD 3.78 billion by 2032, advancing at an aggressive 18.28% CAGR from 2027 to 2032. This segment encompasses fully disposable single-use duodenoscopes, single-use gastroscopes, single-use colonoscopes, and specialized ultra-slim single-use cholangiopancreatoscopes and enteroscopes.

The commercial dominance of single-use endoscopes is driven by the immediate, total elimination of cross-contamination risks, particularly in high-acuity biliary and pancreatic interventions where reusable duodenoscopes have historically caused catastrophic hospital-acquired infections. High-definition chip-on-tip digital visualization, coupled with sterile, pre-calibrated elevator mechanisms and pristine mechanical articulation out of the box, provides gastroenterologists with uncompromised procedural control. Facilities deploying single-use scopes entirely eliminate the recurring capital, labor, and chemical burden of automated endoscope reprocessing, transforming room turnover times and providing an immediate risk-management firewall against institutional healthcare-acquired infection penalties.

Endoscopic Resection and Polypectomy Devices
Endoscopic resection and polypectomy devices accounted for USD 0.55 billion in 2026, following historical revenues of USD 0.34 billion in 2023, USD 0.40 billion in 2024, and USD 0.47 billion in 2025. This segment is projected to reach USD 1.34 billion by 2032, expanding at a 16.00% CAGR from 2027 to 2032. Equipment within this domain includes single-use cold and hot polypectomy snares, endoscopic mucosal resection injection needles, precision electrosurgical endoscopic knives, tissue retractor bands, and submucosal lifting agent delivery catheters.

Demand is fueled by the massive volume of outpatient colorectal cancer screening colonoscopies and the aggressive clinical standard of removing all identified precancerous adenomatous polyps during the initial procedure. High-tensile braided nitinol snares with specialized oval, hexagonal, and crescent loop geometries allow endoscopists to achieve clean, en bloc resection of both pedunculated and challenging flat, sessile polyps while minimizing thermal artifact damage to surrounding mucosal tissue margins. Endoscopic mucosal resection devices have experienced rapid uptake as therapeutic endoscopists increasingly manage early-stage gastrointestinal neoplasms non-operatively within outpatient endoscopy suites, necessitating sterile, single-use dissection knives and high-stability submucosal injection needles.

Biliary and Pancreatic Access Devices
Biliary and pancreatic access devices represented USD 0.48 billion in 2026, rising from USD 0.30 billion in 2023, USD 0.35 billion in 2024, and USD 0.41 billion in 2025. The segment is on track to achieve USD 1.19 billion by 2032, demonstrating a 16.34% CAGR from 2027 to 2032. This category comprises single-use sphincterotomes, ultra-flexible hydrophilic biliary guidewires, multi-lumen stone extraction balloons, pancreaticobiliary dilation catheters, and single-use delivery platforms for plastic and self-expanding metal biliary stents.

The steady expansion of this segment is anchored in the expanding volume of therapeutic endoscopic retrograde cholangiopancreatography interventions performed across the United States for choledocholithiasis, benign biliary strictures, and malignant ductal obstructions. Precision rotational sphincterotomes equipped with insulated tip wires prevent inadvertent thermal injury to adjacent duodenal mucosa while providing exact micro-metric orientation at the twelve o’clock position for rapid biliary duct cannulation. Hydrophilic-coated guidewires engineered with high-torque nitinol cores allow endoscopists to traverse complex, high-grade strictures smoothly, ensuring dependable single-operator catheter exchange without ductal access loss.

Hemostasis and Ligation Devices
Hemostasis and ligation devices accounted for USD 0.38 billion in 2026, expanding from historical figures of USD 0.23 billion in 2023, USD 0.27 billion in 2024, and USD 0.32 billion in 2025. By 2032, the category is projected to reach USD 0.93 billion, reflecting a 16.08% CAGR from 2027 to 2032. Products include through-the-scope single-use rotatable hemostatic clips, endoscopic band ligators for esophageal varices, disposable bipolar and multipolar coagulation probes, and spray hemostasis delivery catheters.

The primary growth catalyst is the clinical imperative to rapidly and definitively arrest acute upper and lower gastrointestinal bleeding, which represents one of the most common and life-threatening emergencies encountered in gastroenterology. Contemporary through-the-scope hemostatic clips feature full 360-degree bidirectional rotation and multi-opening/closing mechanisms, allowing clinicians to precisely appose mucosal tissue margins over bleeding peptic ulcers, arterial spurts, or post-polypectomy mucosal defects before deploying the clip. Single-use endoscopic band ligators provide multi-band sequential firing capabilities for rapid prophylactic and emergency eradication of bleeding esophageal varices in cirrhotic patients, eliminating device jam risks through pre-threaded sterile delivery barrels.

Gastrointestinal Biopsy and Sampling Devices
Gastrointestinal biopsy and sampling devices generated USD 0.24 billion in 2026, having grown from USD 0.16 billion in 2023, USD 0.18 billion in 2024, and USD 0.21 billion in 2025. This category is anticipated to achieve USD 0.52 billion by 2032, expanding at a 13.76% CAGR from 2027 to 2032. Consumable devices include single-use cold and hot biopsy forceps, endoscope biopsy port seals and valves, cytology brush catheters, and specialized endoscopic ultrasound fine-needle aspiration and fine-needle biopsy needles.

This segment creates a foundational, non-discretionary, recurring consumable volume across every diagnostic endoscopy procedure performed in the United States. Disposable biopsy forceps engineered with razor-sharp fenestrated stainless-steel cups and central needle spikes ensure clean tissue bite profiles, maximizing diagnostic histopathological yield while preventing crushing artifact in mucosal tissue specimens evaluating Helicobacter pylori, celiac sprue, or inflammatory bowel disease. Furthermore, the universal adoption of single-use biopsy channel valves and suction buttons has permanently eliminated cross-contamination vectors across scope working ports, establishing mandatory compliance benchmarks in hospital accreditation audits.

Endoscopic Dilation and Retrieval Devices
Endoscopic dilation and retrieval devices represented USD 0.15 billion in 2026, following historical revenues of USD 0.11 billion in 2023, USD 0.12 billion in 2024, and USD 0.13 billion in 2025. The segment is projected to reach USD 0.36 billion by 2032, demonstrating a 15.71% CAGR from 2027 to 2032. This specialized category includes non-compliant controlled-radial-expansion balloon dilators, bougie dilation systems, disposable foreign body retrieval nets, endoscopic grasping forceps, and polyp retrieval baskets.

Intestinal and esophageal strictures resulting from chronic gastroesophageal reflux disease, radiation therapy, anastomotic surgical scarring, and eosinophilic esophagitis require repeated mechanical dilation procedures. Multi-stage controlled-radial-expansion balloons deliver three distinct calibrated pressures and diameters from a single balloon unit, allowing endoscopists to perform progressive, controlled lumen dilation without catheter exchanges under direct endoscopic and fluoroscopic visualization. Concurrently, disposable polyp retrieval nets utilizing micro-mesh fabric pouches provide rapid, complete collection of multiple resected polyps or foreign bodies, preventing tissue aspiration and ensuring comprehensive histological specimen recovery.

By Procedure Type

The U.S. Single-Use Gastroenterology Devices Market by procedure type is segmented into Endoscopic Retrograde Cholangiopancreatography, Colonoscopy and Lower GI Screening, Esophagogastroduodenoscopy, Endoscopic Ultrasound, Gastrointestinal Hemostasis and Emergency Interventions, and Enteroscopy and Capsule Endoscopy Accessories.

Endoscopic Retrograde Cholangiopancreatography
Endoscopic retrograde cholangiopancreatography represents the largest procedural revenue contributor, accounting for USD 1.12 billion in 2026, following historical figures of USD 0.67 billion in 2023, USD 0.79 billion in 2024, and USD 0.94 billion in 2025. This segment is projected to reach USD 2.91 billion by 2032, growing at an aggressive 17.25% CAGR from 2027 to 2032. Procedures include diagnostic cholangiography, biliary sphincterotomy, common bile duct stone clearance, biliary and pancreatic duct stenting, and brush cytology for biliary malignancies.

The commercial volume of this segment is sustained by the intense, urgent clinical necessity of treating life-threatening pancreaticobiliary disorders, combined with the fact that duodenoscopes represent the primary locus of historical cross-contamination outbreaks. Because ERCP is an inherently therapeutic, high-complexity intervention involving fragile immunocompromised patients, health systems have overwhelmingly prioritized single-use duodenoscope conversion in this procedural category. Facilities utilize single-use scopes, pre-sterilized sphincterotomes, single-use guidewires, and disposable extraction balloons, establishing an entirely sterile procedural pathway that guarantees zero pathogen transmission between high-risk biliary cases.

Colonoscopy and Lower GI Screening
Colonoscopy and lower gastrointestinal screening represented USD 0.81 billion in 2026, up from USD 0.48 billion in 2023, USD 0.57 billion in 2024, and USD 0.68 billion in 2025. The segment is on track to reach USD 2.14 billion by 2032, reflecting a 17.58% CAGR from 2027 to 2032. Clinical procedures include average-risk screening colonoscopies, diagnostic surveillance for high-risk adenoma formers, therapeutic polypectomies, colonic decompression, and surveillance examinations for ulcerative colitis and Crohn’s disease.

The expansion of this procedural domain is propelled by the massive demographic influx of screening-eligible individuals following the lowering of the colorectal cancer screening age to 45. Ambulatory surgery centers handling forty to sixty colonoscopies per day per facility face intense operational pressure to maximize room utilization and eliminate reprocessing turnaround bottlenecks. The deployment of lightweight, single-use colonoscopes paired with pre-packaged disposable snares, injection needles, and polyp retrieval traps enables outpatient centers to maintain continuous procedural flow without maintaining multi-million-dollar redundant scope inventories, fundamentally transforming the unit economics of high-throughput colorectal cancer screening.

Esophagogastroduodenoscopy
Esophagogastroduodenoscopy accounted for USD 0.61 billion in 2026, expanding from historical revenues of USD 0.38 billion in 2023, USD 0.44 billion in 2024, and USD 0.52 billion in 2025. The segment is anticipated to achieve USD 1.49 billion by 2032, growing at a 16.04% CAGR from 2027 to 2032. Procedures encompass diagnostic evaluation of intractable dyspepsia, upper gastrointestinal dysphagia workups, surveillance and radiofrequency ablation of Barrett’s esophagus, celiac disease duodenal biopsies, and gastric ulcer surveillance.

Upper gastrointestinal endoscopy is one of the highest-volume outpatient diagnostic procedures in the United States, driven by the epidemic prevalence of gastroesophageal reflux disease and esophageal adenocarcinoma risk. Single-use gastroscopes are rapidly penetrating both hospital outpatient endoscopy departments and specialized esophageal diagnostic centers. The clinical convenience of utilizing an ultra-sterile, immediate-access gastroscope for rapid inpatient bedside evaluations, intensive care consultations, and ambulatory diagnostic evaluations eliminates the delays associated with transporting contaminated scopes through hospital corridors to centralized processing facilities, optimizing clinical response times.

Endoscopic Ultrasound
Endoscopic ultrasound accounted for USD 0.33 billion in 2026, following historical figures of USD 0.19 billion in 2023, USD 0.23 billion in 2024, and USD 0.27 billion in 2025. The segment is projected to reach USD 0.86 billion by 2032, reflecting a 17.31% CAGR from 2027 to 2032. This application includes diagnostic staging of esophageal, gastric, and pancreaticobiliary malignancies, fine-needle biopsy of deep retroperitoneal lymph nodes, transmural pancreatic pseudocyst drainage, and celiac plexus neurolysis for intractable cancer pain.

Endoscopic ultrasound combines high-frequency acoustic imaging with direct endoscopic visualization, requiring specialized, expensive echoendoscopes that feature complex elevator channels and acoustic transducers that are notoriously difficult to clean and susceptible to physical handling damage. Single-use echoendoscopes and specialized single-use fine-needle biopsy devices represent a breakthrough for hospital surgical departments. By eliminating the high repair costs associated with fragile acoustic transducer arrays and preventing elevator bio-burden accumulation, single-use EUS systems provide consistent acoustic imaging fidelity and pristine biopsy needle mechanics for critical oncological staging procedures.

Gastrointestinal Hemostasis and Emergency Interventions
Gastrointestinal hemostasis and emergency interventions generated USD 0.20 billion in 2026, having grown from USD 0.12 billion in 2023, USD 0.14 billion in 2024, and USD 0.17 billion in 2025. By 2032, the category is projected to reach USD 0.48 billion, expanding at a 15.71% CAGR from 2027 to 2032. Indications include emergency intervention for massive peptic ulcer hemorrhage, acute Dieulafoy lesion bleeding, Mallory-Weiss tears, emergency foreign body extractions, and acute lower gastrointestinal diverticular bleeding.

Emergency gastrointestinal interventions occur unpredictably across evening, weekend, and holiday hours when hospital central sterile processing departments operate with skeleton crews or are entirely unstaffed. When a patient arrives in hemorrhagic shock requiring immediate endoscopic hemostasis, nursing staff cannot afford delays waiting for on-call reprocessing technicians to locate, inspect, and disinfect a clean scope. Single-use hemostatic endoscopes, stored pre-packaged and sterile in the emergency department or intensive care unit, provide immediate, plug-and-play therapeutic access within seconds, fundamentally improving clinical survival outcomes in severe gastrointestinal hemorrhage.

Enteroscopy and Capsule Endoscopy Accessories
Enteroscopy and capsule endoscopy accessories generated USD 0.11 billion in 2026, up from USD 0.08 billion in 2023, USD 0.09 billion in 2024, and USD 0.10 billion in 2025. The segment is projected to reach USD 0.24 billion by 2032, growing at a 13.88% CAGR from 2027 to 2032. Applications span single-balloon and double-balloon deep small bowel enteroscopy, spiral enteroscopy accessories, single-use overtubes, and specialized wireless video capsule endoscopy delivery catheters and sensor arrays.

Evaluating obscure gastrointestinal bleeding and deep small bowel Crohn’s disease has historically posed extreme technical challenges due to the length and tortuosity of the small intestine. Disposable enteroscopy overtubes with integrated hydrophilic low-friction inner channels and single-use motor-driven spiral sleeves allow endoscopists to pleat extensive segments of the jejunum and ileum rapidly without mucosal shear trauma. Furthermore, single-use capsule endoscopy delivery devices enable targeted endoscopic placement of video capsules directly into the duodenum in patients with severe gastroparesis or anatomical gastric outlet alterations, expanding diagnostic capabilities across complex inpatient populations.

By Indication

The U.S. Single-Use Gastroenterology Devices Market by indication is segmented into Biliary and Pancreatic Disorders, Colorectal Cancer and Precancerous Polyps, Gastrointestinal Bleeding and Vascular Lesions, Gastroesophageal Reflux Disease and Barrett’s Esophagus, Inflammatory Bowel Disease, and Structural Obstructions and Strictures.

Biliary and Pancreatic Disorders
Biliary and pancreatic disorders represent the largest indication segment, accounting for USD 1.14 billion in 2026, following historical levels of USD 0.69 billion in 2023, USD 0.81 billion in 2024, and USD 0.96 billion in 2025. The category is projected to reach USD 2.95 billion by 2032, advancing at a 17.17% CAGR from 2027 to 2032. Clinical conditions encompass choledocholithiasis, acute and chronic pancreatitis, cholangiocarcinoma, pancreatic ductal adenocarcinoma, and benign biliary strictures following liver transplantation or laparoscopic cholecystectomy.

The commanding revenue share of this indication stems from the exceptional complexity of pancreaticobiliary anatomy and the catastrophic clinical consequences of procedural contamination in an obstructed, sterile biliary tree. Introducing multidrug-resistant bacteria into an obstructed bile duct during ERCP frequently results in lethal suppurative cholangitis and polymicrobial sepsis. Consequently, hepatobiliary specialists and hospital epidemiologists mandate the deployment of single-use duodenoscopes, single-use cholangioscopes, and sterile disposable biliary accessories as the absolute clinical standard of care, ensuring that delicate biliary interventions remain entirely sterile throughout the procedure.

Colorectal Cancer and Precancerous Polyps
Colorectal cancer and precancerous polyps accounted for USD 0.87 billion in 2026, up from USD 0.52 billion in 2023, USD 0.61 billion in 2024, and USD 0.73 billion in 2025. The segment is projected to achieve USD 2.26 billion by 2032, expanding at a 17.25% CAGR from 2027 to 2032. Clinical pathology covers tubular adenomas, sessile serrated lesions, advanced villous adenomas, familial adenomatous polyposis, and early-stage colorectal carcinomas.

Colorectal cancer remains the second leading cause of cancer death in the United States, yet it is almost entirely preventable through the timely detection and resection of precancerous adenomatous polyps. The ongoing nationwide push to screen millions of newly eligible 45-to-49-year-old adults has concentrated immense device utilization within screening colonoscopy suites. Endoscopists require continuous, high-volume replenishment of sterile single-use polypectomy snares, mucosal injection needles for lifting flat lesions, and through-the-scope hemostatic clips to manage immediate post-resection hemorrhage, making colorectal cancer prevention the primary driver of recurring consumable device spend.

Gastrointestinal Bleeding and Vascular Lesions
Gastrointestinal bleeding and vascular lesions accounted for USD 0.48 billion in 2026, having grown from USD 0.29 billion in 2023, USD 0.34 billion in 2024, and USD 0.40 billion in 2025. By 2032, the segment is projected to reach USD 1.19 billion, reflecting a 16.34% CAGR from 2027 to 2032. Indications encompass bleeding gastric and duodenal peptic ulcers, gastric antral vascular ectasia, colonic angiodysplasias, diverticular bleeding, and radiation proctitis.

Acute gastrointestinal hemorrhage represents an acute clinical emergency requiring rapid, multi-modality endoscopic treatment. Gastroenterologists rely heavily on single-use devices that combine mechanical, thermal, and chemical hemostatic mechanisms. Single-use through-the-scope clips that can be rotated, clamped, opened, and repositioned provide mechanical arterial tamponade, while disposable multipolar coagulation probes deliver targeted thermal coagulation without adherence to charred tissue. The unpredictable timing and severe clinical acuity of GI bleeds drive hospital emergency departments to maintain high standing inventories of single-use scopes and sterile hemostasis accessories.

Gastroesophageal Reflux Disease and Barrett’s Esophagus
Gastroesophageal reflux disease and Barrett’s esophagus generated USD 0.35 billion in 2026, expanding from historical figures of USD 0.21 billion in 2023, USD 0.25 billion in 2024, and USD 0.30 billion in 2025. The category is on track to achieve USD 0.88 billion by 2032, demonstrating a 16.61% CAGR from 2027 to 2032. Pathologies include severe erosive esophagitis, peptic esophageal strictures, non-dysplastic Barrett’s esophagus, and high-grade dysplastic intestinal metaplasia.

Chronic GERD affects roughly 20% of the adult American population, driving extensive outpatient screening to identify premalignant Barrett’s esophagus. The standard-of-care protocol mandates systematic four-quadrant mucosal biopsies every two centimeters throughout the affected esophageal segment, creating high demand for sterile disposable jumbo biopsy forceps. Furthermore, treating confirmed dysplasia utilizing single-use endoscopic radiofrequency ablation balloon catheters and focal ablation plates allows clinicians to eradicate precancerous mucosal layers safely, preventing progression to invasive esophageal adenocarcinoma without surgical esophagectomy.

Inflammatory Bowel Disease
Inflammatory bowel disease accounted for USD 0.21 billion in 2026, following historical figures of USD 0.13 billion in 2023, USD 0.15 billion in 2024, and USD 0.17 billion in 2025. The category is projected to reach USD 0.51 billion by 2032, exhibiting a 15.94% CAGR from 2027 to 2032. Clinical indications include ulcerative colitis mucosal surveillance, Crohn’s disease ileocolonic assessment, stricture evaluation, and dysplasia surveillance utilizing targeted chromoendoscopy.

Patients suffering from long-standing inflammatory bowel disease require frequent, lifelong endoscopic surveillance to monitor mucosal healing and detect microscopic neoplastic transformation. Because these patients are frequently maintained on potent systemic immunosuppressive therapies, such as anti-tumor necrosis factor biologics and Janus kinase inhibitors, their susceptibility to nosocomial opportunistic infections is markedly elevated. Treating gastroenterologists strongly advocate for single-use endoscopic platforms and sterile disposable accessories to ensure that immunocompromised IBD patients are never exposed to residual pathogens from prior endoscopic cases.

Structural Obstructions and Strictures
Structural obstructions and strictures generated USD 0.13 billion in 2026, up from USD 0.08 billion in 2023, USD 0.10 billion in 2024, and USD 0.12 billion in 2025. The segment is projected to reach USD 0.33 billion by 2032, growing at a 16.80% CAGR from 2027 to 2032. Pathologies span benign esophageal anastomotic strictures, corrosive chemical strictures, malignant gastric outlet obstructions, pyloric stenosis, and malignant colonic strictures.

Managing gastrointestinal structural narrowing requires specialized single-use mechanical dilation and luminal stenting devices. Clinicians utilize disposable controlled-radial-expansion balloons to restore luminal patency gradually without causing full-thickness transmural perforation. For inoperable malignant obstructions of the esophagus, duodenum, or colon, single-use delivery catheters pre-loaded with self-expanding metal stents provide palliative luminal restoration, enabling patients to maintain oral nutrition and avoid emergency surgical colostomies or feeding tube placements.

By Technology and Modality

The U.S. Single-Use Gastroenterology Devices Market by technology and modality is segmented into Digital Chip-on-Tip CMOS Visualization Platforms, Hybrid Modular Endoscopy Systems, Fully Integrated Ultra-Disposable Scope Units, AI-Enabled and Computer-Aided Diagnostic Consumables, and Specialized Micro-Mechanical Articulation Systems.

Digital Chip-on-Tip CMOS Visualization Platforms
Digital chip-on-tip CMOS visualization platforms represent the largest technological share, accounting for USD 1.46 billion in 2026, following historical levels of USD 0.86 billion in 2023, USD 1.02 billion in 2024, and USD 1.22 billion in 2025. The category is projected to reach USD 3.86 billion by 2032, advancing at a 17.59% CAGR from 2027 to 2032. This technology group comprises single-use endoscopes that incorporate sub-millimeter CMOS sensors, integrated micro-aperture lenses, and distal LED illumination systems directly within the disposable catheter head.

The primary driver of this technology group is the clinical requirement for pristine image resolution that matches traditional reusable video endoscopy. Early single-use prototypes relied on low-resolution image sensors that produced grainy, poorly illuminated video streams with restricted depth of field. Modern wafer-level CMOS packaging delivers full high-definition video feeds with wide-angle dynamic range and high frame rates directly to compact video processors. By locating both the image sensor and the light source at the distal tip, these systems eliminate bulky external light guides, heavy optical cables, and expensive xenon light sources, delivering superior ergonomics and pristine digital visualization for every clinical case.

Hybrid Modular Endoscopy Systems
Hybrid modular endoscopy systems accounted for USD 0.74 billion in 2026, up from USD 0.46 billion in 2023, USD 0.54 billion in 2024, and USD 0.63 billion in 2025. The segment is projected to achieve USD 1.82 billion by 2032, expanding at a 16.19% CAGR from 2027 to 2032. Products include reusable video processing and articulation control handles that interface with sterile, single-use detachable insertion tubes, single-use working channels, or disposable elevator endcaps.

This technology group represents a pragmatically designed intermediate adoption pathway for health systems seeking to mitigate cross-contamination risks while protecting prior capital equipment investments. By replacing the patient-contact components—the flexible insertion tube, biopsy channel, and distal elevator—with single-use sterile modules while retaining the high-value imaging processor and proximal handle mechanics, hospitals significantly reduce per-procedure consumable costs. Furthermore, single-use detachable distal caps for duodenoscopes allow reprocessing technicians full, unhindered mechanical brushing access to the previously sealed elevator space, substantially lowering bio-burden risks without requiring the complete discarding of the scope body.

Fully Integrated Ultra-Disposable Scope Units
Fully integrated ultra-disposable scope units accounted for USD 0.57 billion in 2026, having grown from USD 0.33 billion in 2023, USD 0.39 billion in 2024, and USD 0.47 billion in 2025. By 2032, the segment is projected to reach USD 1.48 billion, reflecting a 17.24% CAGR from 2027 to 2032. Products encompass all-in-one sterile endoscopes where the entire physical unit—distal tip, insertion tube, umbilicus, control handle, valves, and electrical connection cable—is disposed of after a single patient use.

The rapid growth of fully integrated disposable units reflects the clinical mandate for absolute, zero-compromise sterility. In high-volume outpatient centers and emergency departments, handling modular assemblies or cleaning proximal control handles introduces human error and potential contamination vectors. Fully integrated scopes arrive individually sealed, double-pouched, and gamma- or ethylene oxide-sterilized, ready for immediate procedural deployment. Once the intervention is completed, the entire assembly is disconnected and placed directly into specialized recycling or medical disposal receptacles, delivering maximum operational simplicity and complete infection control certainty.

AI-Enabled and Computer-Aided Diagnostic Consumables
AI-enabled and computer-aided diagnostic consumables generated USD 0.26 billion in 2026, expanding from USD 0.15 billion in 2023, USD 0.18 billion in 2024, and USD 0.22 billion in 2025. The segment is on track to achieve USD 0.68 billion by 2032, reflecting a 17.39% CAGR from 2027 to 2032. This domain includes single-use endoscopy systems integrated with cloud-connected edge processing consoles running computer-aided detection and computer-aided characterization neural networks for real-time mucosal polyp identification.

This segment represents the most technologically advanced software-hardware integration within gastroenterology, directly targeting the reduction of missed adenomatous polyps during routine colonoscopy. Edge-computing microchips embedded within the single-use video console process video feeds in real time, placing visual bounding markers around suspected polyps and providing instant optical histological classification based on mucosal pit pattern algorithms. This technology democratizes tertiary-care diagnostic acuity, allowing community gastroenterologists to achieve adenoma detection rates exceeding 40%, directly reducing post-colonoscopy interval colorectal cancer rates.

Specialized Micro-Mechanical Articulation Systems
Specialized micro-mechanical articulation systems accounted for USD 0.15 billion in 2026, following historical figures of USD 0.12 billion in 2023, USD 0.13 billion in 2024, and USD 0.14 billion in 2025. The category is projected to reach USD 0.28 billion by 2032, exhibiting a 10.96% CAGR from 2027 to 2032. This specialized segment comprises proprietary laser-cut stainless-steel bending sections, multi-wire mechanical deflection linkages, and high-tensile torque-transfer braiding engineered specifically for disposable catheter architectures.

Delivering responsive, non-lagging tip articulation without the substantial weight and expense of traditional reusable mechanical assemblies has been a primary engineering challenge for disposable endoscopy. Advanced micro-mechanical systems utilize precision laser-machined vertebrae coupled with ultra-thin, pre-stretched tungsten or stainless-steel steering cables. These linkages allow endoscopists to achieve tight-radius retroflexion within the gastric cardia or cecum with minimal hand force, providing the tactile feedback and mechanical precision required for complex therapeutic maneuvering.

By End User

The U.S. Single-Use Gastroenterology Devices Market by end user is segmented into Ambulatory Surgery Centers and Outpatient Endoscopy Centers, Hospital Outpatient Endoscopy Departments, Inpatient Tertiary and Quaternary Hospitals, Emergency Departments and Intensive Care Units, and Academic Medical Centers and GI Research Institutes.

Ambulatory Surgery Centers and Outpatient Endoscopy Centers
Ambulatory surgery centers and outpatient endoscopy centers represent the largest and fastest-expanding end-user category, accounting for USD 1.36 billion in 2026, up from USD 0.79 billion in 2023, USD 0.94 billion in 2024, and USD 1.13 billion in 2025. The segment is projected to reach USD 3.68 billion by 2032, expanding at an 18.06% CAGR from 2027 to 2032. This segment comprises independent, physician-owned endoscopy centers, corporate ambulatory surgery networks, and specialized outpatient digestive health clinics.

The overwhelming revenue leadership of ambulatory surgery centers stems from commercial payer site-of-care steerage mandates, superior operational cost structures, and high daily procedural throughput. ASCs operate with lean administrative overhead and lack the physical space, capital reserves, and dedicated processing personnel required to maintain multi-station automated endoscope reprocessing rooms. Single-use gastroenterology platforms eliminate capital depreciation, eliminate chemical bio-hazard compliance burdens, and compress room turnaround times from forty-five minutes down to fifteen minutes. This operational acceleration allows outpatient centers to schedule additional procedural slots daily, dramatically increasing facility fee revenues while providing pristine clinical safety.

Hospital Outpatient Endoscopy Departments
Hospital outpatient endoscopy departments accounted for USD 0.97 billion in 2026, having grown from USD 0.60 billion in 2023, USD 0.70 billion in 2024, and USD 0.82 billion in 2025. The category is projected to reach USD 2.42 billion by 2032, exhibiting a 16.46% CAGR from 2027 to 2032. This segment encompasses hospital-based outpatient surgical suites managing high volumes of elective colorectal screenings, diagnostic upper endoscopies, and outpatient therapeutic interventions.

Hospital outpatient departments face intense pressure to balance patient clinical acuity with operational profitability. While HOPDs historically utilized existing centralized hospital reprocessing facilities, persistent bottlenecks, scope transport delays, and elevated infection risks have driven departmental medical directors to adopt single-use devices aggressively. Furthermore, favorable Medicare Outpatient Prospective Payment System rules, including dedicated transitional pass-through payments for single-use duodenoscopes, allow hospital outpatient departments to recover device acquisition costs directly, providing the financial incentive required to transition high-risk procedures toward single-use instrumentation.

Inpatient Tertiary and Quaternary Hospitals
Inpatient tertiary and quaternary hospitals accounted for USD 0.49 billion in 2026, up from USD 0.31 billion in 2023, USD 0.36 billion in 2024, and USD 0.42 billion in 2025. The segment is projected to reach USD 1.14 billion by 2032, demonstrating a 15.11% CAGR from 2027 to 2032. These high-volume, multi-specialty facilities manage complex inpatient admissions, advanced surgical interventions, severe organ failure, and acute infectious disease complications.

Inpatient hospitals manage the highest clinical acuity patients in the healthcare system, including organ transplant recipients, oncology patients undergoing aggressive chemotherapy, and patients suffering from multidrug-resistant infections. For these critically ill populations, exposure to contaminated flexible endoscopes represents an acute, frequently fatal hazard. Inpatient hospital infection control committees mandate the deployment of single-use duodenoscopes and sterile therapeutic consumables for all inpatient ERCP procedures to insulate vulnerable patients from nosocomial outbreaks, mitigating catastrophic financial penalties under Medicare’s Hospital-Acquired Condition Reduction Program.

Emergency Departments and Intensive Care Units
Emergency departments and intensive care units generated USD 0.21 billion in 2026, having expanded from USD 0.13 billion in 2023, USD 0.15 billion in 2024, and USD 0.18 billion in 2025. The segment is on track to achieve USD 0.51 billion by 2032, advancing at a 15.94% CAGR from 2027 to 2032. This clinical setting includes emergency trauma bays, medical intensive care units, and surgical critical care wards managing acute medical crises.

Emergency departments and intensive care units require instantaneous, unhindered access to sterile endoscopy platforms twenty-four hours a day, seven days a week. In acute clinical scenarios, such as massive upper gastrointestinal variceal bleeding or acute food bolus esophageal impaction, clinical teams cannot tolerate delays waiting for a reusable scope to be delivered from central sterile processing and leak-tested. Single-use endoscopes, maintained in compact, sterile packaging within emergency supply rooms, can be connected to portable video consoles within seconds, providing immediate diagnostic and therapeutic intervention at the patient bedside.

Academic Medical Centers and GI Research Institutes
Academic medical centers and GI research institutes accounted for USD 0.15 billion in 2026, following historical figures of USD 0.09 billion in 2023, USD 0.11 billion in 2024, and USD 0.13 billion in 2025. The category is projected to reach USD 0.37 billion by 2032, growing at a 16.24% CAGR from 2027 to 2032. This group includes university-affiliated teaching hospitals, medical school clinical facilities, and specialized digestive disease clinical trial networks.

Academic medical centers serve as the primary clinical proving grounds for next-generation gastroenterology innovations, conducting pivotal clinical trials evaluating single-use scope optics, mechanical maneuverability, and artificial intelligence diagnostic integration. These elite institutions train gastroenterology fellows and advanced endoscopy residents, establishing baseline technical familiarity with single-use platforms among emerging practitioners. Equipment vendors actively partner with academic medical faculties to conduct rigorous comparative health-economic analyses, generate peer-reviewed post-market surveillance data, and refine ergonomic chassis designs prior to widespread commercial rollout.

Regional Insights: Where the Market is Growing Fastest

The U.S. Single-Use Gastroenterology Devices Market is geographically segmented into four primary commercial regions: the South, the West, the Midwest, and the Northeast. Regional market performance is governed by underlying structural dynamics, including state-level ambulatory surgery center density, regional demographic aging patterns, commercial and Medicare payer reimbursement policies, state hospital association infection reporting mandates, and the geographic distribution of major academic digestive health centers.

South

The South represents the largest overall commercial regional market for single-use gastroenterology devices in the United States, generating USD 1.17 billion in 2026, up from historical levels of USD 0.69 billion in 2023, USD 0.82 billion in 2024, and USD 0.98 billion in 2025. The Southern regional market is projected to reach USD 3.06 billion by 2032, expanding at an aggressive 17.38% CAGR from 2027 to 2032. The South’s commercial leadership is anchored by its vast population concentration, nation-leading rates of population growth driven by domestic migration, an expanding retiree demographic with high digestive disease prevalence, and an expansive network of corporate-backed ambulatory surgery centers. Furthermore, states across the South exhibit elevated incidences of obesity, type 2 diabetes, non-alcoholic steatohepatitis, and colorectal malignancies, generating massive daily procedural volumes across both inpatient hospital systems and outpatient endoscopy suites.

Texas represents the dominant economic engine within the Southern single-use gastroenterology landscape, supported by a population exceeding 30 million residents, extensive metropolitan medical centers, and a highly favorable regulatory environment for independent ambulatory surgical facilities. Major metropolitan healthcare epicenters, including the Texas Medical Center in Houston, Dallas-Fort Worth, Austin, and San Antonio, host some of the highest-volume gastroenterology procedural networks in the world. Texas health systems, including Baylor Scott & White Health, Memorial Hermann Health System, and Houston Methodist, have executed aggressive departmental transitions toward single-use duodenoscopes and sterile therapeutic consumables to insulate their massive procedural pipelines from cross-contamination liabilities. The high prevalence of biliary lithiasis and metabolic liver disease across South and Central Texas creates constant demand for ERCP access catheters, single-use sphincterotomes, and disposable extraction balloons. Furthermore, the rapid expansion of private equity-backed digestive health management organizations across suburban Dallas and Houston has driven heavy capital deployment into single-use endoscopic platforms to optimize outpatient room turnover and maximize daily screening volumes.

Florida represents the second-largest state market within the South, distinguished by an expansive geriatric population, high per-capita Medicare enrollment, and dense concentrations of specialized retirement communities with intensive healthcare utilization patterns. Metropolitan areas such as Miami-Fort Lauderdale, Tampa-St. Petersburg, Orlando, and Jacksonville support hundreds of Medicare-certified outpatient endoscopy centers performing high-volume diagnostic colonoscopies, Barrett’s esophagus surveillance, and upper gastrointestinal interventions. Florida’s demographic profile results in an extraordinarily high clinical caseload of diverticular disease, polyposis syndromes, gastrointestinal vascular ectasias, and pancreatic neoplasms. Outpatient facilities across Florida have rapidly embraced single-use colonoscopes and disposable hemostasis clips to maintain high-velocity procedural schedules while eliminating the regulatory compliance burdens associated with state healthcare inspection audits of chemical endoscope reprocessing suites. Furthermore, major tertiary referral centers, such as the AdventHealth network, Baptist Health South Florida, and the University of Miami Health System, serve as regional anchors for complex hepatobiliary interventions, driving extensive procurement of advanced single-use duodenoscopes and single-use cholangiopancreatoscopes.

North Carolina and Georgia represent rapidly expanding single-use device hubs fueled by dynamic technology corridors, high population in-migration, and premier academic health systems. The Research Triangle corridor in North Carolina, anchored by Duke University Health System, UNC Health, and Wake Forest Baptist Health, alongside the Charlotte metropolitan healthcare corridor, exhibits sophisticated clinical technology adoption. These institutions have been early clinical trial leaders in evaluating single-use duodenoscope biomechanics and real-world infection rates, establishing progressive procurement protocols that favor disposable platforms across their regional hospital networks. Georgia, propelled by the expansive Atlanta metropolitan healthcare ecosystem and systems such as Emory Healthcare, Piedmont Healthcare, and Wellstar Health System, demonstrates aggressive adoption of single-use endoscopy across both urban trauma centers and suburban outpatient endoscopy facilities seeking to mitigate central sterile processing staffing constraints.

Tennessee, Virginia, and the broader Gulf Coast states—including Louisiana, Alabama, and Mississippi—sustain substantial, steady demand across diagnostic and therapeutic single-use gastroenterology devices. Tennessee serves as the corporate headquarters for major national hospital management corporations, including HCA Healthcare in Nashville, which exercises immense enterprise-wide procurement leverage over medical device supply contracts. Corporate supply chain directives originating in Nashville increasingly emphasize infection de-risking through standardized single-use endoscope contracts across hundreds of affiliated hospital facilities nationwide. Virginia features affluent, high-density pet-owning and suburban populations across Northern Virginia and the Richmond corridor, where healthcare systems invest heavily in cutting-edge outpatient endoscopy infrastructure. In rural and community hospital settings across Alabama, Mississippi, and Louisiana, where central sterile processing departments struggle with acute technician shortages and volatile operating budgets, single-use gastroenterology devices provide a dependable, turn-key clinical solution that guarantees uncompromised infection control without requiring expensive automated reprocessing capital infrastructure.

West

The West represents the fastest-growing single-use gastroenterology devices region through 2032, accounting for USD 0.85 billion in 2026, following historical revenues of USD 0.50 billion in 2023, USD 0.60 billion in 2024, and USD 0.71 billion in 2025. The Western market is projected to reach USD 2.22 billion by 2032, demonstrating a 17.35% CAGR from 2027 to 2032. The region’s exceptional growth trajectory is propelled by early clinical innovation adoption, aggressive implementation of hospital infection transparency standards, highly capitalized ambulatory surgery networks, and progressive environmental circularity initiatives that align with single-use device recycling programs.

California represents the undisputed commercial anchor of the Western region and the single largest state market for single-use gastroenterology devices in the entire United States. Supported by a population approaching 40 million residents and an extensive network of world-renowned academic medical centers and integrated delivery networks, California stands at the forefront of clinical protocol modernization. Health systems such as Kaiser Permanente, Sutter Health, Cedars-Sinai Medical Center, Stanford Health Care, and the University of California medical campuses (UCLA, UCSF, UC Davis, UC San Diego, UC Irvine) exercise immense influence over national standard-of-care guidelines. Following several widely publicized duodenoscope-linked carbapenem-resistant Enterobacteriaceae outbreaks in Los Angeles and the San Francisco Bay Area, California healthcare providers enacted some of the most stringent endoscope culturing and infection surveillance mandates in the nation. This regulatory rigor accelerated the rapid displacement of reusable duodenoscopes in favor of fully single-use platforms. Furthermore, California’s progressive environmental policies have compelled single-use device manufacturers to establish robust, closed-loop plastic recycling programs, allowing health systems to achieve zero-infection clinical safety while meeting state-mandated hospital waste reduction goals.

Washington and Oregon represent mature, highly sophisticated gastroenterology markets characterized by progressive healthcare policy frameworks, concentrated integrated delivery networks, and strong clinical research capabilities. The Greater Seattle metropolitan corridor, alongside Portland, Oregon, exhibits exceptional clinical focus on patient safety, quality metrics, and preventive care delivery. Prominent regional health systems, including Providence St. Joseph Health, UW Medicine, and Legacy Health, have systematically integrated single-use endoscopes into their emergency departments, intensive care units, and outpatient endoscopy suites. Gastroenterologists across the Pacific Northwest demonstrate high clinical acceptance of computer-aided diagnostic algorithms and AI-enabled single-use endoscopy platforms, utilizing intelligent mucosal lesion recognition to maximize adenoma detection rates during high-volume colorectal cancer screening workflows.

Colorado, Arizona, and Utah represent dynamic, rapidly expanding interior Western markets fueled by substantial population influxes, expanding corporate biotechnology corridors, and the rapid development of specialized outpatient surgical centers. Colorado’s Front Range corridor, spanning Denver, Boulder, and Colorado Springs, represents a major national hub for healthcare excellence, anchored by UCHealth and the Denver Health system. Endoscopy suites throughout Colorado invest heavily in specialized single-use therapeutic accessories, including through-the-scope hemostatic clips, endoscopic mucosal resection devices, and multi-stage balloon dilators to manage complex gastroenterology caseloads. Arizona, anchored by Phoenix, Scottsdale, and Tucson, features an expanding year-round geriatric and retiree demographic, driving intense demand for screening colonoscopies, ERCP procedures, and gastrointestinal hemostasis devices across facilities such as the Mayo Clinic in Arizona and Banner Health. Utah, Nevada, Idaho, and Montana provide additional commercial velocity, driven by expanding suburban medical networks and regional referral centers that deploy single-use endoscopes to overcome geographic and logistical barriers associated with transporting contaminated scopes across vast rural hospital networks.

Midwest

The Midwest represents a mature, highly resilient single-use gastroenterology devices market, generating USD 0.68 billion in 2026, up from historical levels of USD 0.42 billion in 2023, USD 0.49 billion in 2024, and USD 0.58 billion in 2025. The Midwestern market is projected to reach USD 1.67 billion by 2032, expanding at a 16.15% CAGR from 2027 to 2032. The region’s commercial landscape is defined by massive academic medical powerhouses, large non-profit healthcare systems, extensive manufacturing corridors, and a disciplined approach to healthcare capital allocation that places an intense focus on total cost of ownership, risk mitigation, and quantifiable clinical return on investment.

Illinois and Ohio represent the primary device revenue drivers within the Midwest. The Chicago metropolitan area encompasses one of the densest and most lucrative healthcare markets in the nation, featuring major academic medical centers such as Northwestern Memorial Hospital, the University of Chicago Medical Center, and Rush University Medical Center, complemented by extensive suburban hospital networks including Advocate Health Care and NorthShore University HealthSystem. Chicago facilities have transitioned significant portions of their inpatient and emergency gastrointestinal procedures to single-use platforms, prioritizing immediate procedural readiness and the eradication of hospital-acquired infection risks. Ohio features a formidable healthcare infrastructure anchored by the world-renowned Cleveland Clinic, OhioHealth, and The Ohio State University Wexner Medical Center. Cleveland Clinic’s Digestive Disease & Surgery Institute, internationally celebrated for clinical innovation in advanced endoscopy, has conducted extensive health-economic and clinical utility analyses on single-use duodenoscopes and cholangioscopes, setting national clinical adoption benchmarks that accelerate device penetration across regional community hospital networks.

Michigan, Indiana, and Wisconsin provide substantial, stable market demand across academic health centers, regional hospital systems, and rural healthcare delivery networks. Michigan’s healthcare market, centered on Detroit, Ann Arbor, and Grand Rapids, and anchored by the University of Michigan Health System, Henry Ford Health, and Corewell Health, exhibits strong procurement of single-use therapeutic accessories, polypectomy snares, and single-use gastroscopes. Indiana features the headquarters of major medical device distribution organizations, vibrant healthcare systems in Indianapolis, and Indiana University Health, which serves as a premier national referral destination for complex biliary and pancreatic endoscopy. Wisconsin represents a highly progressive outpatient endoscopy market, where health systems such as Aurora Health Care and the University of Wisconsin Hospital and Clinics invest heavily in single-use colonoscopy systems and disposable biopsy accessories to streamline high-throughput colorectal cancer screening programs across suburban and community clinics.

Minnesota, Iowa, Missouri, and the Plains States—including Kansas, Nebraska, and the Dakotas—represent critical clinical research territories alongside highly dependable community healthcare markets. Minnesota hosts the globally preeminent Mayo Clinic in Rochester, which consistently dictates clinical practice guidelines and evaluates cutting-edge medical device technology. Mayo Clinic’s extensive clinical evaluation of single-use endoscopy systems has provided authoritative validation of their optical resolution, therapeutic mechanical precision, and infection prevention efficacy, profoundly influencing hospital procurement committees nationwide. Missouri, anchored by major clinical hubs in St. Louis and Kansas City, encompassing BJC HealthCare and Saint Luke’s Health System, demonstrates rapid adoption of single-use endoscopes within emergency departments and intensive care units to guarantee immediate, round-the-clock procedural readiness for acute gastrointestinal bleeding interventions.

Northeast

The Northeast represents an exceptionally sophisticated, high-value regional market, accounting for USD 0.48 billion in 2026, having grown from USD 0.31 billion in 2023, USD 0.35 billion in 2024, and USD 0.41 billion in 2025. The Northeastern market is projected to reach USD 1.17 billion by 2032, demonstrating a 15.99% CAGR from 2027 to 2032. While the Northeast is geographically more compact than the South or West, it features the nation’s highest geographic density of elite academic medical schools, premier cancer institutes, prestigious private tertiary hospitals, and highly discerning clinical faculties that establish rigorous clinical evidence standards for device adoption.

New York represents the economic cornerstone of the Northeastern single-use gastroenterology market, driven by the extraordinary concentration of world-class medical institutions across the New York City metropolitan area, Long Island, and Westchester County, complemented by extensive upstate healthcare networks. Institutions such as NewYork-Presbyterian Hospital, Mount Sinai Health System, NYU Langone Health, Memorial Sloan Kettering Cancer Center, and Northwell Health operate endoscopy suites with procedural caseloads that rank among the highest in the world. Constrained urban real-estate footprints across Manhattan make the construction and expansion of multi-room chemical endoscope reprocessing suites prohibitively expensive. Single-use gastroenterology platforms provide New York City hospital administrators with a space-saving clinical solution that eliminates chemical storage rooms and automated reprocessing footprints, allowing hospitals to convert physical space into revenue-generating procedural bays. Upstate New York, supported by the University of Rochester Medical Center and Albany Medical Center, generates steady commercial demand for single-use therapeutic ERCP catheters and disposable hemostasis instrumentation.

Pennsylvania represents the second-largest state market within the Northeast, supported by dense healthcare systems across Philadelphia and Pittsburgh. The University of Pennsylvania Health System (Penn Medicine), Jefferson Health, and Temple Health in Philadelphia, alongside the University of Pittsburgh Medical Center (UPMC) and Allegheny Health Network in western Pennsylvania, represent major institutional buyers of advanced single-use gastroenterology platforms. Penn Medicine and UPMC host globally renowned divisions of gastroenterology that manage high volumes of complex therapeutic biliary endoscopies, interventional endoscopic ultrasound procedures, and early-stage gastrointestinal cancer resections. These academic institutions mandate single-use duodenoscope deployment across their high-risk hepatobiliary services, establishing regional infection control standards that compel suburban and rural affiliated community hospitals to follow suit.

Massachusetts, New Jersey, and Connecticut represent affluent, clinically progressive healthcare markets characterized by high health insurance penetration, leading biomedical research hubs, and rapid clinical adoption of single-use medical innovations. The Boston metropolitan healthcare corridor, anchored by Massachusetts General Hospital, Brigham and Women’s Hospital, Beth Israel Deaconess Medical Center, and the Dana-Farber Cancer Institute, serves as a premier national testing ground for advanced optical imaging, edge artificial intelligence, and single-use endoscopic instrumentation. Boston-area gastroenterologists demand uncompromising optical performance and precision mechanical articulation, accelerating the clinical transition toward advanced chip-on-tip single-use platforms. New Jersey’s dense healthcare networks, including Hackensack Meridian Health and RWJBarnabas Health, alongside Connecticut’s Yale New Haven Health, exhibit robust procurement of single-use colonoscopy systems and disposable polypectomy accessories to service dense suburban patient populations seeking low-risk outpatient screening procedures.

Maine, New Hampshire, Vermont, and Rhode Island complete the Northeastern landscape, representing stable healthcare markets characterized by centralized regional referral centers, such as Dartmouth-Hitchcock Medical Center in New Hampshire and Maine Medical Center in Portland. In these northern New England settings, where hospital networks span extensive rural geographies, transporting contaminated flexible endoscopes between satellite clinics and centralized reprocessing hubs introduces severe logistical delays and substantial scope damage risks. Deploying single-use gastroenterology devices eliminates regional transport logistics entirely, ensuring that community healthcare facilities maintain uninterrupted, fully sterile procedural capabilities across all routine and emergency gastrointestinal interventions.

Key Market Players

The competitive landscape of the U.S. Single-Use Gastroenterology Devices Market is defined by intense technological rivalry, aggressive intellectual property expansion, and strategic commercial maneuvering between diversified global medical device conglomerates, established endoscopy leaders, and specialized single-use medtech innovators.

Highly relevant players operating in the U.S. single-use gastroenterology devices industry include:

Boston Scientific Corporation
Ambu A/S
Olympus Corporation
PENTAX Medical (HOYA Group)
Karl Storz SE & Co. KG
CONMED Corporation
Cook Medical
Merit Medical Systems, Inc.
STERIS plc
Medi-Globe Technologies GmbH
EndoFresh (Shenzhen Xian An Medical Technology)
Laborie Medical Technologies
Micro-Tech Endoscopy
GI View Ltd.
Fujifilm Holdings America Corporation

Boston Scientific Corporation represents the undisputed commercial and clinical pioneer in the U.S. single-use flexible gastroenterology market, having commercialized the EXALT Model D single-use duodenoscope, which secured the FDA’s Breakthrough Device designation and established the benchmark for single-use duodenoscope adoption. Boston Scientific leverages an unmatched, comprehensive portfolio spanning single-use visualization platforms, through-the-scope hemostatic clips, endoscopic resection devices, biliary access catheters, and guidewires. The company’s commercial dominance is sustained by its enterprise-level hospital contracting power, deep clinical relationships with interventional endoscopists, and aggressive investment in next-generation chip-on-tip imaging and digital processing consoles.

Ambu A/S is a dedicated global trailblazer in single-use endoscopy, having successfully translated its market leadership in single-use pulmonary bronchoscopy into the flexible gastroenterology arena. Ambu’s gastroenterology portfolio is anchored by the aScope Gastro single-use gastroscope, the aScope Duodeno, and the aScope Colon single-use colonoscope, all interfacing with its proprietary, portable aBox digital video processing console. Ambu’s competitive advantage lies in its high-volume, automated manufacturing infrastructure, which drives down per-unit production costs and enables aggressive, competitive pricing models that appeal directly to high-throughput ambulatory surgery centers seeking to optimize per-procedure operating margins.

Olympus Corporation represents the historic global market leader in flexible gastrointestinal endoscopy, commanding an extensive installed base of capital endoscopy towers across U.S. healthcare facilities. To protect its market share against pure-play single-use disruptors, Olympus has executed a sophisticated hybrid innovation strategy, commercializing single-use duodenoscope platforms alongside advanced reusable scopes featuring single-use disposable distal endcaps. Olympus differentiates itself through its legendary optical glass engineering, precision mechanical articulation, and expansive clinical education network, while expanding its disposable therapeutic accessory portfolio to maintain customer brand loyalty across hospital surgical departments.

PENTAX Medical, operating as a specialized medical division of the HOYA Group, has established a formidable presence across U.S. gastroenterology through its innovative approach to infection prevention and hygiene design. PENTAX commercialized the DEC single-use distal endcap duodenoscope, which combines the optical and mechanical performance of a reusable scope body with a sterile, disposable elevator mechanism that eliminates bio-burden accumulation in the distal recess. PENTAX Medical continues to expand its single-use consumable footprint, delivering high-precision biopsy forceps, polyp snares, and advanced imaging processors engineered to enhance mucosal vascular contrast and optimize diagnostic accuracy.

Karl Storz SE & Co. KG brings world-renowned German surgical engineering and high-definition visualization expertise to the flexible single-use endoscopy sector. Historically celebrated for its rigid endoscopic towers and minimally invasive laparoscopic instrumentation, Karl Storz has expanded aggressively into flexible single-use platforms for gastroenterology, emergency medicine, and critical care. The company’s competitive strength centers on its modular camera control units, uncompressed digital video transmission, and seamless integration with hospital-wide operating room integration suites and electronic medical record platforms.

CONMED Corporation is an established American medical technology leader with a deep, specialized presence in gastrointestinal endoscopy accessories, electrosurgical generators, and fluid management systems. CONMED commands substantial market share across single-use polypectomy snares, mucosal injection needles, biliary sphincterotomes, and endoscopic hemostasis devices. Its commercial strategy relies on providing comprehensive, high-reliability disposable consumable suites that integrate seamlessly with existing hospital capital infrastructure, supported by flexible group purchasing organization contracts and competitive volume discounting.

Cook Medical is an internationally recognized pioneer in minimally invasive interventional devices, commanding deep brand equity and clinical loyalty among interventional gastroenterologists. Cook Medical’s gastroenterology division delivers an exhaustive portfolio of specialized single-use biliary and pancreatic access devices, including the advanced Cotton-Leung biliary stents, hydrophilic-coated guidewires, multi-stage stone extraction balloons, and precision echoendoscopic fine-needle biopsy systems. Cook distinguishes itself through its uncompromising focus on mechanical engineering precision, catheter trackability, and dedicated clinical education programs supporting complex interventional endoscopy.

Merit Medical Systems, Inc. operates as a leading designer and manufacturer of specialized single-use disposable devices utilized in interventional gastroenterology, radiology, and oncology. Merit’s gastrointestinal portfolio encompasses the Elation balloon dilation catheters, disposable inflation devices, biopsy forceps, non-vascular self-expanding metal stents, and specialized fluid management accessories. Merit Medical differentiates itself through its vertical manufacturing integration, proprietary polymer extrusion technologies, and responsive custom-procedure tray packaging, which streamlines nursing preparation workflows in high-volume procedural suites.

STERIS plc is a global titan in infection prevention, contamination control, and surgical operating room infrastructure. While historically renowned for manufacturing automated endoscope reprocessors, chemical sterilants, and scope drying cabinets, STERIS has aggressively diversified into single-use gastroenterology endoscopy consumables. Through its specialized endoscopy division, STERIS delivers a comprehensive array of disposable procedural accessories, including single-use biopsy valves, polyp traps, transport containment bags, single-use mechanical cleaning brushes, and endoscopic hemostatic clips, positioning itself as an indispensable total-solution partner for hospital infection control and sterile processing departments.

Medi-Globe Technologies GmbH, integrated within the international medtech landscape, is a prominent developer of specialized single-use endoscopic accessories for interventional gastroenterology and pulmonology. The company is particularly recognized for its advanced ultrasound-guided biopsy instrumentation, single-use fine-needle aspiration systems, extraction baskets, and foreign body retrieval devices. Medi-Globe’s competitive advantage lies in its German-engineered precision manufacturing, exceptional needle sharpness, and ergonomic handle mechanisms that enhance diagnostic tissue yield during deep oncological staging procedures.

EndoFresh (Shenzhen Xian An Medical Technology) has emerged as an agile, disruptive global innovator in disposable digestive endoscopy, commercializing an innovative all-in-one single-use gastroscope and single-use colonoscope system paired with a compact, ultra-portable workstation. EndoFresh specifically targets the acute operational needs of outpatient surgical facilities, intensive care units, and emergency departments, delivering cost-effective single-use visualization that eliminates initial capital hurdles. Its rapid expansion across international markets and entry into the U.S. landscape highlights the intensifying price-to-performance competition in single-use optics.

Laborie Medical Technologies is a specialized global medical technology company dedicated to digestive health and pelvic floor disorders. Following strategic acquisitions of specialized endoscopy innovators, Laborie has expanded its portfolio to include high-resolution esophageal manometry catheters, disposable pH monitoring accessories, and specialized single-use therapeutic endoscopy devices. Laborie differentiates itself through its deep focus on functional gastrointestinal diagnostics, providing gastroenterologists with integrated diagnostic platforms that evaluate motility disorders and gastroesophageal reflux disease with pristine disposable sensor precision.

Micro-Tech Endoscopy represents one of the fastest-growing single-use gastroenterology accessory manufacturers in the United States, operating as the American commercial subsidiary of Micro-Tech (Nanjing) Co., Ltd. Micro-Tech has captured substantial market share across through-the-scope hemostatic clips, non-thermal cold snares, disposable biopsy forceps, and dilation balloons. The company’s competitive strategy is anchored in delivering premium-grade mechanical performance, ultra-fast supply chain turnaround, and aggressive, disruptive pricing structures that provide hospital procurement directors and ASC administrators with immediate operational margin expansion.

GI View Ltd. is an innovative commercial-stage medical device enterprise focused on transforming colorectal cancer screening through its proprietary single-use colonoscopy technology, including self-propelled and disposable imaging platforms. GI View addresses the clinical limitations of traditional colonoscopy by engineering single-use scopes that utilize soft pneumatic propulsion and multi-directional visualization to traverse the tortuous colon with minimal mucosal shear force. This technology aims to reduce patient discomfort, minimize sedation requirements, and eliminate scope reprocessing overhead entirely.

Fujifilm Holdings America Corporation is an established global leader in optical engineering, digital radiography, and medical endoscopy. Fujifilm has responded to the single-use imperative by introducing innovative disposable components, single-use duodenoscope platforms, and hybrid systems featuring detachable distal caps, alongside its flagship ELUXEO 7000 video endoscopy capital towers. Fujifilm differentiates itself through its proprietary 4-LED Multi-Light technology, Linked Color Imaging, and Blue Light Imaging optical processing algorithms, providing endoscopists with exceptional micro-vascular mucosal contrast while expanding its sterile single-use accessory lines to safeguard patient clinical safety.

Recent Developments

The U.S. single-use gastroenterology devices industry has undergone profound corporate consolidation, technological acceleration, and regulatory transformation since 2024.

A defining structural development has been the systematic issuance of updated safety recommendations and post-market surveillance final rules by the U.S. Food and Drug Administration regarding flexible endoscope cross-contamination. Between 2024 and 2026, the FDA’s Center for Devices and Radiological Health synthesized real-world data from mandated 522 post-market surveillance studies conducted across dozens of American healthcare systems. The empirical findings demonstrated that even under optimal, manufacturer-certified automated high-level disinfection protocols, reusable duodenoscopes with fixed endcaps exhibited persistent microbial contamination rates between 5% and 8%. In response, the FDA formally advised healthcare facilities to transition entirely toward innovative duodenoscopes with disposable components or fully single-use, sterile duodenoscope platforms, establishing an authoritative regulatory precedent that has effectively eliminated capital purchasing of fixed-elevator reusable scopes across the country.

Strategic reimbursement policy updates enacted by the Centers for Medicare & Medicaid Services have fundamentally reshaped procedural billing and device acquisition economics. Under the Outpatient Prospective Payment System and Ambulatory Surgical Center final rules, CMS established and subsequently extended dedicated Healthcare Common Procedure Coding System Level II C-codes (such as C1747) and Transitional Pass-Through payment mechanisms for innovative single-use duodenoscopes. These regulatory payment policies provide qualifying hospital outpatient departments and ambulatory surgery centers with incremental, supplemental Medicare reimbursement that covers the device acquisition cost over and above standard Comprehensive Ambulatory Payment Classifications. This financial de-risking has removed the primary institutional hurdle to single-use adoption, allowing community healthcare providers to deploy single-use platforms immediately without eroding departmental operating margins.

Product innovation within artificial intelligence-driven diagnostic visualization has achieved commercial integration between 2024 and 2026. Leading single-use endoscopy developers have successfully integrated real-time computer-aided detection and computer-aided characterization algorithms directly into the micro-processing architectures of their portable, single-use display consoles. The FDA granted multiple 510(k) clearances for edge-AI single-use colonoscopy systems capable of analyzing sixty-frame-per-second video streams to identify subtle flat adenomas and diminutive sessile serrated polyps with sensitivity rates exceeding 93%. These intelligent single-use platforms bridge the diagnostic skill gap among endoscopists, elevating baseline adenoma detection rates in community outpatient centers to levels historically confined to elite academic research institutions.

The medical device manufacturing landscape has simultaneously experienced an aggressive push toward circular plastics recycling and environmental life-cycle mitigation. The rapid, widespread adoption of single-use endoscopy generated institutional concerns regarding medical plastic waste generation across healthcare systems committed to corporate decarbonization and sustainability goals. In response, major device manufacturers partnered with specialized healthcare recycling consolidators to deploy nationwide closed-loop recovery initiatives. Advanced single-use scopes introduced in 2025 and 2026 feature modular mechanical designs engineered for rapid disassembly, utilizing bio-based, gamma-compatible polymer housings that can be ground into sterile plastic pellets following advanced chemical sterilization. These secondary materials are repurposed into non-clinical industrial supply chains, providing healthcare chief sustainability officers with the environmental data required to endorse single-use conversions.

Corporate mergers, strategic acquisitions, and supply chain consolidations have redefined competitive boundaries across the gastrointestinal consumable ecosystem. Diversified medical conglomerates have systematically acquired agile single-use accessory innovators to secure proprietary patents in through-the-scope hemostatic clipping, continuous mucosal lifting agents, and rotatable sphincterotome articulation. Furthermore, leading hospital purchasing networks, including Vizient, Premier, and HealthTrust, executed multi-year, enterprise-wide standardization contracts with primary single-use endoscope manufacturers, securing volume-discounted pricing tiers and guaranteed inventory replenishment schedules across thousands of affiliated hospital endoscopy suites and ambulatory surgical networks.

The clinical research domain has reinforced market velocity through the publication of major prospective, randomized multi-center clinical trials comparing single-use flexible endoscopes directly against premium reusable platforms. These landmark studies, conducted across prominent American academic health centers, demonstrated absolute non-inferiority in technical procedural success rates, cannulation velocity, and tissue biopsy yields across complex ERCP, diagnostic colonoscopy, and therapeutic upper gastrointestinal procedures. Crucially, the single-use study cohorts demonstrated an absolute 0% incidence of device-transmitted microbial infection, providing unassailable, peer-reviewed clinical evidence that has empowered hospital infection control directors and risk management committees to mandate single-use adoption across high-acuity surgical services.

Conclusion

The U.S. Single-Use Gastroenterology Devices Market is positioned to expand from USD 3.18 billion in 2026 to approximately USD 8.12 billion by 2032, supported by an aggressive 16.89% CAGR from 2027 to 2032. Historical market development from USD 1.92 billion in 2023, USD 2.26 billion in 2024, and USD 2.68 billion in 2025 demonstrates the structural resilience, non-discretionary clinical demand, and continuous capital expansion of the single-use gastroenterology device industry across macroeconomic cycles.

The underlying growth thesis is propelled by irreversible structural transformations within infection control epidemiology, hospital operating economics, and clinical care delivery. Reusable flexible endoscopes, engineered with complex internal working lumens and delicate mechanical elevator mechanisms, possess fundamental design vulnerabilities that preclude guaranteed high-level decontamination in real-world healthcare settings. The persistent risk of transmitting lethal multidrug-resistant pathogens, combined with punitive regulatory sanctions and catastrophic legal liabilities, has compelled hospital leadership to abandon legacy reprocessing models in favor of guaranteed, unit-dosed sterile single-use platforms.

The commercial marketplace is defined by the rapid displacement of heavy, depreciable capital equipment towers in favor of agile, predictable, procedure-linked operating expenditure frameworks. Healthcare systems and ambulatory surgery centers are navigating severe central sterile processing technician shortages, escalating chemical bio-hazard compliance overhead, and intensifying pressure to compress procedural room turnaround times. Single-use gastroenterology devices eliminate the need for multi-million-dollar automated endoscope reprocessing rooms, hazardous sterilizing chemicals, and extensive manual cleaning labor, allowing outpatient endoscopy facilities to accelerate patient throughput and optimize facility fee revenues.

Single-use endoscopes, encompassing duodenoscopes, gastroscopes, colonoscopes, and echoendoscopes, will maintain their position as the premier capital-displacing growth engine, driven by wafer-level CMOS optical sensor miniaturization, micro-LED illumination, and precision micro-mechanical articulation that matches the visualization and maneuverability of premium reusable systems. Concurrently, specialized single-use therapeutic consumables—encompassing through-the-scope hemostatic clips, nitinol braided polypectomy snares, precision rotatable sphincterotomes, and multi-stage balloon dilators—will capture immense recurring commercial value across millions of annual screening and therapeutic interventions.

Geographically, the South will maintain absolute market revenue leadership, propelled by massive population in-migration, dense geriatric demographics, and expansive networks of corporate-backed ambulatory surgery centers across Texas and Florida. The West will lead the nation in technological growth velocity, driven by California’s aggressive hospital infection transparency standards, early clinical adoption of computer-aided diagnostic algorithms, and pioneering closed-loop medical plastics recycling initiatives. The Midwest will continue to provide a deeply resilient foundation of capital procurement across world-renowned academic medical institutions and large integrated healthcare systems that prioritize total cost of ownership and clinical risk mitigation. The Northeast will remain the country’s most specialized, evidence-driven regional market, distinguished by elite academic medical centers and prestigious cancer institutes that set national standard-of-care guidelines.

For medical device manufacturers, institutional healthcare investors, distributor networks, and hospital procurement executives, competitive advantage through 2032 will belong to enterprises that deliver comprehensive, interconnected gastroenterology ecosystems. Hardware optical excellence alone is no longer sufficient to secure market dominance. Winning vendors will successfully combine high-definition chip-on-tip visualization with intelligent edge artificial intelligence, comprehensive portfolios of high-precision therapeutic accessories, flexible group purchasing contracts, closed-loop environmental recycling logistics, and responsive nationwide distribution networks. Companies that master this integrated clinical and operational delivery model will capture the greatest lifetime value and define the standard of care across the expanding U.S. single-use gastroenterology landscape through 2032.